Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04100447
Other study ID # LBS-IST-POI-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 5, 2018
Est. completion date December 1, 2020

Study information

Verified date December 2020
Source Centinela Hospital Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of LB1148 in subjects undergoing elective bowel resection. During abdominal surgery, surgeons handle, manipulate, and often make incisions in the bowel. These actions can create bruising, lesions, and microscopic damage to the bowel, which may allow digestive enzymes to cross the intestinal mucosal barrier potentially resulting in injury both locally and remotely. Leaking digestive enzymes may delay return of normal gastrointestinal (GI) function, lead to a lack of motility in the intestine (ileus), and promote the formation of intestinal scar tissue (adhesions).


Description:

The intestinal mucosal barrier plays a key role in both acute critical care medical conditions as well as burdensome chronic diseases. Healthy maintenance of the intestinal mucosal barrier requires oxygenation and blood flow and avoidance of mechanical or physical injury. Potent digestive enzymes are maintained within the intestine as long as normal blood flow continues and no damage or disturbances to the wall occur. Breakdown of the intestinal mucosal barrier can be produced by wide variety of events. These include prolonged low blood pressure (e.g. during shock), disruption of blood flow (e.g. during ischemia), and physical and mechanical perturbations (e.g. during trauma or abdominal surgery). One of the key advances toward the use of LB1148 to reduce postoperative complications was the learning that with more subtle perturbations of the mucosal barriers, such as during abdominal surgery, intraluminal pancreatic digestive enzymes played a role in GI dysfunction. Perioperative oral administration of LB1148 in preclinical models was sufficient to reduce the delayed return of GI function. Furthermore, the reduction in pancreatic digestive enzyme-induced tissue damage resulted in a profound reduction in postoperative adhesion formation. Together, these preclinical studies provide evidence that blocking pancreatic digestive enzymes with LB1148 in the intestine reduces local tissue damage, preserves GI function, and reduces adhesion formation.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date December 1, 2020
Est. primary completion date March 20, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - Subjects will be eligible for participation in the study only if they meet ALL of the following inclusion criteria: 1. Scheduled to undergo an elective (non-emergent) bowel resection. This includes any subject in which a resection of the small intestine, colon, or rectum is performed for any elected indication. 2. The subject has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent. Exclusion Criteria: - Subjects will not be eligible for participation in the study if they meet ANY of the following exclusion criteria: 1. Subjects who are < 18 or > 85 years of age. 2. Subjects who require emergency bowel surgery. 3. Subjects who have had 2 or more abdominal surgeries, excluding the current, for inflammatory bowel disease (IBD), including, but not limited to, IBD, Crohn's Disease, or ulcerative colitis. Note: This does not apply to previous surgeries such as hernia repair unrelated to IBD. 4. Subjects who meet the American Society of Anesthesiologists (ASA) definition for Class 4 or 5 disease. 5. Known inability to take the study drug orally (i.e. complete small bowel obstruction). 6. Subjects with contraindications or potential risk factors to taking TXA. These include: 1. Known sensitivity to TXA 2. Recent craniotomy (past 30 days) 3. Active cerebrovascular bleed 4. Active thromboembolic disease (such as deep vein thrombosis, pulmonary embolism, cerebral thrombosis, ischemic stroke, or acute coronary syndrome) 5. Acute promyelocytic leukemia taking all-trans retinoic acid for remission induction 6. Continuing use of a combined hormonal contraceptive and/or combined hormonal replacement therapy (including combined hormonal pill, patch, or vaginal ring). 7. Subjects who have the following risk factors for thromboembolic disease: 1. Known medical history of congenital or acquired thrombophilia such as, but not limited to: - Sickle cell disease - Nephrotic syndrome - Factor V Leiden - Prothrombin gene mutation - Protein C or S deficiency - Antithrombin III deficiency - Antiphospholipid syndrome 2. Neurologic paresis, partial paralysis, or paralysis 3. Presence of a pacemaker 4. History of pulmonary embolism, deep vein thrombosis, cerebrovascular accident, or retinal venous/arterial occlusion. 8. History of or current seizure disorder. 9. Subjects with myeloproliferative disorders. 10. Subjects with a Body Mass Index (BMI) > 40. 11. Any other condition that, in the opinion of the Investigator, would preclude the subject from being an appropriate candidate for the study, including severe renal or hepatic impairment. 12. Planned treatment with alvimopan (EnteregĀ®) during study participation period. 13. Subjects who have received any other investigational therapy within 4 weeks. 14. Subjects with a history of chronic opioid usage, defined by the American Pain Society as daily or near-daily use of opioids for at least 90 days. 15. Female subjects of childbearing potential with a positive urine or serum pregnancy test or who are not taking (or not willing to take) acceptable birth control measures (abstinence, intrauterine device, contraceptive implant or barrier method) through Study Day 30. Additionally, those women who are lactating and insist on breast feeding within 5 days of the last dose of study drug, are excluded. 16. Subjects with a known history of radiation enteritis.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tranexamic Acid
A total of 700 mL of study drug should be completely consumed orally 2-12 hours prior to surgery as a split dose; 350 mL 6-12 hours prior to surgery and the remaining 350 mL 2-6 hours prior to surgery.

Locations

Country Name City State
United States Centinela Hospital Medical Center Inglewood California

Sponsors (1)

Lead Sponsor Collaborator
Ronald Hurst, MD, FACS

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of participants who experience treatment-emergent adverse events (TEAEs) The number of participants who experience treatment-emergent adverse events (TEAEs) with Investigator-specified relationship to LB1148 and assessment of severity From first study drug dosing through Day 30
Secondary Number of participants who require a nasogastric (NG) tube placement Necessity for nasogastric (NG) tube placement During hospitalization (up to 14 days postoperatively), yes or no
Secondary Average length of time an NG tube was in place, if required Time NG tube was in place, if needed During hospitalization (up to 14 days postoperatively), in hours
Secondary Number of participants who experience post surgical vomiting Presence of postsurgical vomiting During hospitalization (from surgical closure to up to 14 days postoperatively), yes or no
Secondary Average number of vomiting episodes, when present Number of vomiting episode(s) During hospitalization (from surgical closure to up to 14 days postoperatively), number of total episodes
Secondary Average time to first flatus following surgery Time to first flatus During hospitalization (from surgical closure to up to 14 days postoperatively), in hours
Secondary Average time to first bowel movement following surgery Time to first bowel movement During hospitalization (from surgical closure to up to 14 days postoperatively), in hours
Secondary Average time to tolerate a liquid diet following surgery Time to toleration of a liquid diet During hospitalization (from surgical closure to up to 14 days postoperatively), in hours
Secondary Average time to tolerate a solid diet after surgery Time to toleration of a solid diet During hospitalization (from surgical closure to up to 14 days postoperatively), in hours
Secondary Average time to hospital discharge order Time to hospital discharge order written During hospitalization (from admission to up to 14 days postoperatively), in hours
See also
  Status Clinical Trial Phase
Terminated NCT00065234 - Acupuncture to Prevent Postoperative Bowel Paralysis (Paralytic Ileus) Phase 2
Completed NCT01156129 - Interventions to Decrease the Impact of Post-OPerative Ileus After Liver Transplant or Resection Surgery Phase 1
Recruiting NCT05712525 - Gut Recovery In Patients Following Surgery
Completed NCT06338813 - Digital Manometry for Intra-Abdominal Pressure Measurement in Ileus N/A
Recruiting NCT05315765 - Development of a Patient Reported Outcome Measure for GastroIntestinal Recovery
Completed NCT02161367 - Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery Phase 4
Completed NCT03711487 - The Effect of Foeniculum Vulgare Ironing on Gastrointestinal Recovery After Colorectal Resection Phase 2
Completed NCT00528970 - A Study Evaluating Intravenous (IV) MOA-728 for the Treatment of Postoperative Ileus (POI) in Participants After Ventral Hernia Repair Phase 3
Not yet recruiting NCT04001985 - Nasogastric Tube Clamping Trial vs. Immediate Removal N/A
Completed NCT02836470 - A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection Phase 2
Active, not recruiting NCT03795467 - Peripheral Perfusion Index, Haemoglobin and Blood Transfusion in Acute Surgical Patients
Completed NCT01143259 - Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use N/A
Terminated NCT03352414 - Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC Phase 2
Not yet recruiting NCT04305730 - Use of Pedometer Following Radical Cystectomy N/A
Completed NCT02760290 - Comparison of Extraperitoneal and Intraperitoneal Cesarean Technique N/A
Active, not recruiting NCT02399605 - Subcutaneous Electrical Stimulation in the Prevention of Postoperative Ileus N/A
Completed NCT00388258 - Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus Phase 3
Terminated NCT05470387 - A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection Phase 3
Completed NCT00205842 - Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus Phase 3
Enrolling by invitation NCT05298774 - Myoelectric Activity Following Colorectal Surgery and Return of Bowel Function N/A